2005
DOI: 10.1001/archderm.141.9.1173
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2006
2006
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(10 citation statements)
references
References 5 publications
0
10
0
Order By: Relevance
“…Moderate toxicities: Treatment is hydrocortisone (2.5% cream), clindamycin (1% gel), or pimecrolimus (Elidel; Novartis Pharmaceuticals Corporation, East Hanover, NJ) (1% cream), with the addition of either doxycycline (100 mg, po twice a day [bid]) or minocycline (100 mg, po bid) [8,53,54]. The EGFRI dosage should not be altered for moderate toxicities.…”
Section: Effective Management Of Egfri-associated Cutaneous Toxicitiesmentioning
confidence: 99%
“…Moderate toxicities: Treatment is hydrocortisone (2.5% cream), clindamycin (1% gel), or pimecrolimus (Elidel; Novartis Pharmaceuticals Corporation, East Hanover, NJ) (1% cream), with the addition of either doxycycline (100 mg, po twice a day [bid]) or minocycline (100 mg, po bid) [8,53,54]. The EGFRI dosage should not be altered for moderate toxicities.…”
Section: Effective Management Of Egfri-associated Cutaneous Toxicitiesmentioning
confidence: 99%
“…28 Prophylactic therapy with tetracyclines, including minocycline and lymecycline, has been shown to be effective in blocking the emergence of the eruption associated with cetuximab treatment. 29 A number of studies have found that the presence and severity of rash are indicators of tumor response as well as overall survival. [30][31][32][33][34] Other studies failed to show the association of rash and tumor response, rash and tumor survival, or rash and both tumor response or survival.…”
Section: Epidermal Growth Factor Receptor Inhibitorsmentioning
confidence: 99%
“…Pustular folliculitis and nail fold symptoms such as perionychial abscesses and pyogenic granulomas have been observed with both monoclonal antibodies and small molecule tyrosine kinase inhibitors, suggesting that neutrophilic inflammation may be a class effect of targeted therapies interfering with EGFR signaling [6,7,8,9,10]. The present case suggests that EGFR-inhibitor-associated generalized xerotic dermatitis may be an additional clinical manifestation of the neutrophilic inflammation pattern associated with EGFR inhibition.…”
Section: Introductionmentioning
confidence: 75%